Testing IMM01 + Tiselizumab for Hodgkin lymphoma after immunotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two drugs (IMM01 and Tiselizumab) for people with classical Hodgkin lymphoma that has stopped responding to standard immunotherapy. The goal is to see if this combination works better than standard chemotherapy options your doctor might choose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with classical Hodgkin lymphoma (a specific type of lymphoma).
- Your cancer must have stopped responding to a PD-1 or PD-L1 inhibitor (a type of immunotherapy drug like Keytruda or Opdivo) and you have tried all other available treatments.
- Your bone marrow and major organs must be working well enough (determined by blood tests and scans).
- You cannot have had any cancer treatment in the last 4 weeks.
- You cannot have ever received a drug that targets CD47 or SIRPα (a type of experimental therapy).
- You cannot have HIV, active autoimmune disease requiring treatment in the last 2 years, or a history of severe allergic reactions to similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
This trial tests a combination of an immunotherapy drug (anti-PD-1 antibody) and radiation therapy for people with newly diagnosed, early-stage classic Hodgkin lymphoma that does not have certain risk factors. The goal is to see if this approach works well and has fewer side effects.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This trial studies whether adding zimberelimab (an immune system drug) to standard AVD chemotherapy works better for newly diagnosed early-stage Hodgkin lymphoma. It may help improve control of the cancer, especially when it can’t be fully cured with simpler treatment alone.
Hear when a new Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.